Eli Lil­ly’s Moun­jaro peak sales could now top $68B – an­a­lyst; Elon Musk’s brain-chip com­pa­ny reels in $280M

A few months ago, BMO Cap­i­tal an­a­lyst Evan Seiger­man es­ti­mat­ed Eli Lil­ly’s type 2 di­a­betes drug Moun­jaro would have more than $50 bil­lion in peak sales. On Tues­day, he bumped that es­ti­mate up to $68.7 bil­lion.

One rea­son for the boost? Lil­ly re­port­ed Moun­jaro’s con­sen­sus-bust­ing sales in its sec­ond-quar­ter earn­ings on Tues­day, along with an an­tic­i­pat­ed FDA ap­proval in obe­si­ty this year and his as­sess­ment of the drug’s “un­in­hib­it­ed” de­mand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER